(E)-2-(β-bromovinyl)quinoline | 350038-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (E)-2-(β-bromovinyl)quinoline
• 英文别名: (E)-1-bromo-2-(2-quinolyl)ethene；(E)-2-(2-bromovinyl)quinoline；(E)-2-(β-bromovinyl)-quinoline；E-1-bromo-2-(2-quinolyl)-ethene；2-[(E)-2-bromoethenyl]quinoline
• CAS: 350038-13-0
• 化学式: C₁₁H₈BrN
• 分子量: 234.095
• InChiKey: KRKTYQUSRQFVQW-BQYQJAHWSA-N

物化性质

• 沸点：
  336.0±17.0 °C(Predicted)
• 密度：
  1.515±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-乙炔喹啉 、 (E)-2-(β-bromovinyl)quinoline 在 四氢吡咯 、 copper(l) iodide 、 四(三苯基膦)钯 作用下， 以 四氢呋喃 为溶剂， 以20%的产率得到
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections

  摘要：

  We report the synthesis of substituted quinolines and their in vitro biological evaluation against the causal agents of cutaneous leishmaniasis, visceral leishmaniasis, African trypanosomiasis and Chagas' disease. Furthermore, several quinolines have also been tested for their anti-retroviral activity in HIV-1 infected cells. The structure activity relationships of these new synthetic compounds are discussed and emphasis was placed on the treatment of leishmania/HIV co-infections. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.007
• 作为产物：
  描述：

  喹啉-2-甲醛 在 iron(III)-acetylacetonate 、 异丙基氯化镁 、 三苯基膦 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (E)-2-(β-bromovinyl)quinoline
  参考文献：
  名称：

  钯催化乙烯基溴化物，三氟甲磺酸酯，甲苯磺酸酯和壬酸酯的二氟甲基化

  摘要：

  描述了在温和条件下二，三或四取代乙烯基溴，三氟甲磺酸酯，甲苯磺酸酯和壬二酸酯的钯催化二氟甲基化。该反应可耐受各种官能团，例如溴化物，氯化物，氟化物，酯，胺，腈和受保护的羰基，因此提供了制备二氟甲基化烯烃的一般途径。

  DOI：

  10.1002/chem.201500551

文献信息

• Substituted quinolines for the treatment of protozoa and retrovirus co-infections
  申请人：Fakhfakh Mohamed

  公开号：US20050165052A1

  公开（公告）日：2005-07-28

  The invention relates to the use of quinolines having general formula (1), wherein R 1 denotes H; alkyl C 1 -C 15 ; alkenyl or alkynyl C 2 -C 15 ; —CHO; heteroaryl; alkyl C 1 -C 15 or alkenyl or alkynyl C 2 -C 7 comprising at least one substituent selected from among O, halogen, —OH, —CHO, —COOH, aryloxycarbonyl, alkyloxycarbonyl C 2 -C 8 , alkenyloxycarbonyl C 3 -C 9 , nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C 1 -C 7 , thioalkyl or aminoalkyl C 1 -C 7 ; alkenyl C 2 -C 7 bearing at least one substituent selected from among NH 2 , aleoxy C 1 -C 7 , phenoxy, cycloakyl C 3 -C 6 or heteroaryloxy, alkenyl or alkynyl C 2 -C 15 comprising at least one trialkylsilyl C 1 -C 7 ; R 2 , in position 3, 6 or 8, denotes H; halogen; —OH; —CHO; —COOH; alkyl or aleoxy C 1 -C 7 ; —NH2; alkenyl C 2 -C 7 ; or alkynyl C 2 -C 10 ; R 1 and R 2 do not both denote H. The invention is used for the preparation of a medicine to treat protozoan and retrovirus co-infections.

  本发明涉及使用通式（1）的喹啉，其中R1表示H; 烷基C1-C15; 烯基或炔基C2-C15; -CHO; 杂环芳基; 烷基C1-C15或烯基或炔基C2-C7，包括至少一种取代基，所述取代基从O，卤素，-OH，-CHO，-COOH，芳基氧羰基，烷氧羰基C2-C8，烯基氧羰基C3-C9，腈，芳基，杂环芳基，芳基磺酰基，烷基磺酰基C1-C7，硫代烷基或氨基烷基C1-C7中选择; 烯基C2-C7具有从NH2，烷氧基C1-C7，苯氧基，环烷基C3-C6或杂环氧基，烯基或炔基C2-C15包括至少一个三烷基硅基C1-C7; R2，在位置3、6或8，表示H; 卤素; -OH; -CHO; -COOH; 烷基或烷氧基C1-C7; -NH2; 烯基C2-C7; 或炔基C2-C10; R1和R2不能同时表示H。该发明用于制备治疗原虫和逆转录病毒共感染的药物。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US20130116233A1

  公开（公告）日：2013-05-09

  The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及一种新型化合物，其化学式为I，它们是磷酸二酯酶10A的抑制剂，并且用于制备药物，因此适用于治疗或控制从神经系统疾病和精神疾病中选择的医学疾病，改善与这些疾病相关的症状，并减少这些疾病的风险。
• Practical Synthesis of (<i>Z</i>)-Polyaromatic and Heteroaromatic Vinylacetylenes
  作者：Anthony Hayford、Joseph Kaloko、Salwa El-Kazaz、Gwen Bass、Cheryl Harrison、Thomas Corprew

  DOI：10.1021/ol0508173

  日期：2005.6.1

  [reaction: seet text] Two synthetic routes to several (Z)-polyaromatic and heteroaromatic substituted vinylacetylenes are described. The nature of aryl- or heteroaryl-substituted carboxaldehyde used as starting material dictated the choice of Wittig salt employed. A very attractive way to construct polyaromatic and pyridine-containing enynes is the reaction of polyaromatic and pyridine-containing aldehydes

  [反应：seet text]描述了到几种（Z）-聚芳族和杂芳族取代的乙烯基乙炔的两种合成路线。用作原料的芳基或杂芳基取代的甲醛的性质决定了所用维蒂希盐的选择。构造聚芳族和含吡啶的烯炔的一种非常有吸引力的方法是在叔丁醇钾存在下，聚芳族和含吡啶的醛与溴甲基三苯基溴化phosph的反应，然后进行Sonogashira甲硅烷基化反应（方法B）。
• Direct Synthesis of Monofunctionalized Indolizine Derivatives Bearing Alkoxymethyl Substituents at C-3 and Their Benzofused Analogues
  作者：Joseph Kaloko、Anthony Hayford

  DOI：10.1021/ol051860t

  日期：2005.9.1

  inorganic base (KOH, K2CO3, CsF, or KF) serendipitously gave 3-alkoxylmethylindolizines and the corresponding 1-alkoxymethylpyrrolo [1,2-a]quinolines and not the anticipated desilylated vinylacetylene derivatives. A mechanistic possibility for this unexpected chemical transformation is suggested.

  [反应：见正文]在适当的无机碱（KOH，K2CO3，CsF或KF）存在下，用几种醇在回流下处理（Z）-2-吡啶和喹啉甲硅烷基化的乙烯基乙炔，偶然产生了3-烷氧基甲基吲哚并相应的化合物。 1-烷氧基甲基吡咯并[1,2-a]喹啉，而不是预期的去甲硅烷基乙炔衍生物。建议这种意外的化学转化的机械可能性。
• Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US09273068B2

  公开（公告）日：2016-03-01

  The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式（I）的新化合物，其中Het，A，Q，X1，X2，X3，R1和R2在规范中有定义，它们是磷酸二酯酶10A的抑制剂，并且用于制造药物，因此适用于治疗或控制选择的医学疾病，包括神经系统疾病和精神障碍，改善与此类疾病相关的症状，并降低此类疾病的风险。